ERBB2 and breast cancer: Therapeutic antibodies such as rituximab (anti-CD20 mAb) and trastuzumab or pertuzumab (both anti-HER2 mAb) as well as different combined therapies have clearly improved the treatment outcome of patients with B-cell lymphoma or breast cancer, respectively (24, 25).